Savara Revenue and Competitors
Estimated Revenue & Valuation
- Savara's estimated annual revenue is currently $6.8M per year.
- Savara received $47.0M in venture funding in October 2017.
- Savara's estimated revenue per employee is $162,714
- Savara's total funding is $261.1M.
- Savara's current valuation is $140.1M. (January 2022)
Employee Data
- Savara has 42 Employees.
- Savara grew their employee count by 17% last year.
Savara Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $26.7M | 133 | 20% | N/A | N/A |
#2 | $13.5M | 67 | 6% | N/A | N/A |
#3 | $3.5M | 66 | -3% | N/A | N/A |
#4 | $62.5M | 0 | N/A | N/A | N/A |
#5 | $8.8M | 41 | 5% | N/A | N/A |
#6 | $58.3M | 491 | 28% | N/A | N/A |
#7 | $21.3M | 94 | 7% | N/A | N/A |
#8 | $78.6M | 382 | 8% | N/A | N/A |
#9 | $12.3M | 46 | -8% | N/A | N/A |
#10 | $6M | 29 | 7% | N/A | N/A |
What Is Savara?
Savara Inc. is an orphan lung disease company. Savara's pipeline comprises: Molgradex, an inhaled granulocyte-macrophage colony-stimulating factor, or GM-CSF, in Phase 3 development for PAP, and in Phase 2a development for NTM lung infection; and AeroVanc, a Phase 3 stage inhaled vancomycin for treatment of MRSA infection in cystic fibrosis. Savara's strategy involves expanding its pipeline of potentially best-in-class products through indication expansion, strategic development partnerships and product acquisitions, with the goal of becoming a leading company in its field. Savara's management team has significant experience in orphan drug development and pulmonary medicine, in identifying unmet needs, developing and acquiring new product candidates, and effectively advancing them to approvals and commercialization. More information can be found at www.savarapharma.com. (Twitter: @SavaraPharma)
keywords:Biotechnology,Healthcare,Medical Devices,Pharmaceuticals
$261.1M
Total Funding
42
Number of Employees
$6.8M
Revenue (est)
17%
Employee Growth %
$140.1M
Valuation
N/A
Accelerator
Savara's People
| Name | Title | Email/Phone |
|---|---|---|
1 | EVP Global Technical Operations | Reveal Email/Phone |
2 | Head Global Advocacy Relations and Patient Engagement | Reveal Email/Phone |
3 | SVP, General Counsel | Reveal Email/Phone |
4 | Chief Operating Officer | Reveal Email/Phone |
5 | Sr. Office Manager & Executive Administrator | Reveal Email/Phone |
6 | Corporate Controller and Senior Director Accounting | Reveal Email/Phone |
7 | Executive Director, Head Data Management and Biostatistics | Reveal Email/Phone |
8 | Head Clinical Operations | Reveal Email/Phone |
9 | CFO | Reveal Email/Phone |
10 | Chief Business Officer | Reveal Email/Phone |
Savara News
Savara is a clinical stage biopharmaceutical company focused on rare respiratory diseases. Our lead program, molgramostim nebulizer solution, is...
Savara Inc (NASDAQ:SVRA - Get Rating) - Analysts at Piper Sandler issued their Q1 2023 earnings per share estimates for Savara in a research...
Savara is a clinical stage biopharmaceutical company focused on rare respiratory diseases. Our lead program, molgramostim nebulizer solution, is...
AUSTIN, Texas - Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, announced that the first patient has been dosed in the pivotal IMPALA-2 clinical trial. IMPALA-2 is a Phase 3 trial designed to evaluate the efficacy and safety of molgram ...
AUSTIN, Texas--(BUSINESS WIRE)--Mar 15, 2021-- Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today announced the closing of its previously announced underwritten public offering of 57,479,978 shares of its common stock, including 11,694,150 shares sold pursuant to the exercise in ...
Other Companies in Austin
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $8.4M | 42 | -5% | N/A |
#2 | $9.9M | 42 | 8% | N/A |
#3 | $6.9M | 42 | 14% | $14.8M |
#4 | $10.6M | 42 | -11% | N/A |
#5 | $8.4M | 42 | N/A | N/A |
Savara Funding
| Date | Amount | Round | Lead Investors | Reference |
|---|---|---|---|---|
| 2009-06-11 | $0.8M | A | Article | |
| 2012-06-13 | $8.6M | B | The Keiretsu Forum | Article |
| 2013-03-21 | $16.0M | B | Tech Coast Angels | Article |
| 2014-06-13 | $4.5M | Undisclosed | Article | |
| 2014-10-07 | $10.0M | Undisclosed | Article | |
| 2015-12-22 | $18.5M | Undisclosed | Article | |
| 2016-03-02 | $20.0M | C | Article | |
| 2017-05-02 | $15.0M | Undisclosed | Silicon Valley Bank | Article |
| 2017-06-05 | $46.0M | Undisclosed | Jefferies LLCS | Article |
| 2017-10-30 | $47.0M | Undisclosed | Article |